CA2643145C - Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates - Google Patents
Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates Download PDFInfo
- Publication number
- CA2643145C CA2643145C CA2643145A CA2643145A CA2643145C CA 2643145 C CA2643145 C CA 2643145C CA 2643145 A CA2643145 A CA 2643145A CA 2643145 A CA2643145 A CA 2643145A CA 2643145 C CA2643145 C CA 2643145C
- Authority
- CA
- Canada
- Prior art keywords
- amido
- alkyl
- hydroxyl
- nitro
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77678506P | 2006-02-24 | 2006-02-24 | |
US60/776,785 | 2006-02-24 | ||
US78436306P | 2006-03-21 | 2006-03-21 | |
US60/784,363 | 2006-03-21 | ||
PCT/US2007/004427 WO2007100563A2 (en) | 2006-02-24 | 2007-02-20 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2643145A1 CA2643145A1 (en) | 2007-09-07 |
CA2643145C true CA2643145C (en) | 2014-04-29 |
Family
ID=38308626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2643145A Expired - Fee Related CA2643145C (en) | 2006-02-24 | 2007-02-20 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates |
Country Status (7)
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090053137A1 (en) * | 2006-03-15 | 2009-02-26 | Moore Dennis A | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof |
US20100055043A1 (en) * | 2006-10-30 | 2010-03-04 | Moore Dennis A | Poly-Halo Metal X-ray Contrast Agents |
US9005577B2 (en) * | 2008-04-30 | 2015-04-14 | Siemens Medical Solutions Usa, Inc. | Substrate based PET imaging agents |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
EP3544964B1 (en) | 2016-11-28 | 2020-06-17 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
SI3568205T1 (sl) | 2017-01-12 | 2023-12-29 | Radiomedix Inc. | Zdravljenje rakastih celic, ki prekomerno izražajo receptorje za somatostatin, z uporabo derivatov okreotida, kelatiranih v radioizotope |
AU2019382881A1 (en) | 2018-11-23 | 2021-05-20 | Bayer Aktiengesellschaft | Formulation of contrast media and process of preparation thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI48507C (fi) | 1972-06-29 | 1974-10-10 | Orion Yhtymae Oy | Menetelmä metallispesifisten atsoväriaineiden kiinnittämiseksi silloit tajaryhmän avulla kiinteään kantaja-ainekseen, erikoisesti selluloosak uituun. |
JPS6048916A (ja) | 1983-08-29 | 1985-03-16 | Risuburan Prod:Kk | 白髪を黒くする整髪用乳化物の製造方法 |
MX174467B (es) * | 1986-01-23 | 1994-05-17 | Squibb & Sons Inc | 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos |
CN1016693B (zh) * | 1987-06-05 | 1992-05-20 | 北京工业大学 | 新顺铂铬合物的制备方法 |
EP0420942A1 (en) * | 1988-06-24 | 1991-04-10 | The Dow Chemical Company | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
US5559149A (en) * | 1990-01-29 | 1996-09-24 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions containing retinoids |
US5186923A (en) * | 1990-10-10 | 1993-02-16 | Brigham And Womens Hospital | Enhancement of cellular accumulation of lipophilic cationic organometallic compounds by reduction of intramembrane potential |
US5147632A (en) * | 1990-10-31 | 1992-09-15 | Warner-Lambert Company | Anti-plaque compositions comprising a combination of morpholinoamino alcohol and chelating agent |
US5310539A (en) * | 1991-04-15 | 1994-05-10 | Board Of Regents, The University Of Texas System | Melanin-based agents for image enhancement |
MX9305039A (es) * | 1992-08-19 | 1994-05-31 | Mallinckrodt Medical Inc | Ligandos para ga-68 para aplicaciones cardiacas de tep. |
JPH1053515A (ja) | 1996-08-09 | 1998-02-24 | Ajinomoto Co Inc | 皮膚外用剤 |
JPH10130155A (ja) | 1996-10-28 | 1998-05-19 | Chiyuuyakuken:Kk | 病変組織治療用組成物、その製法およびその用途 |
EP0976392A1 (en) | 1998-07-29 | 2000-02-02 | Unilever Plc | Liquid compositions comprising antioxidants and ED3A-derived chelating surfactants as stabilizers |
US6685914B1 (en) * | 1999-09-13 | 2004-02-03 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
PE20011099A1 (es) | 2000-02-14 | 2001-11-23 | Procter & Gamble | Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene oxidacion reducida |
US20030161862A1 (en) * | 2000-03-28 | 2003-08-28 | Susumu Hizukuri | Bacterial growth regulators or inhibitors with the use of 1,5-d-anhydrofructose |
US6602989B1 (en) * | 2000-05-17 | 2003-08-05 | The Research Foundation Of State University Of New York | Synthesis, characterization, and application of pyridylazo bioconjugates as diagnostic and therapeutic agents |
US6710192B2 (en) * | 2001-10-16 | 2004-03-23 | Arco Chemical Technology, L.P. | Dense phase epoxidation |
WO2003045449A1 (fr) * | 2001-11-26 | 2003-06-05 | Yugen Kaisha Okada Giken | Agent desodorisant et preparation de shampooing cosmetique le contenant |
US7176239B2 (en) * | 2003-07-11 | 2007-02-13 | Suming Wang | Methods and compositions for treatment of Ataxia-telangeictasia |
CA2631784A1 (en) | 2005-11-29 | 2007-06-07 | Mallinckrodt Inc. | Bifunctional metal chelating conjugates |
-
2007
- 2007-02-20 JP JP2008556387A patent/JP2009527559A/ja active Pending
- 2007-02-20 KR KR1020087020548A patent/KR20080099279A/ko not_active Application Discontinuation
- 2007-02-20 US US12/280,370 patent/US8119103B2/en not_active Expired - Fee Related
- 2007-02-20 WO PCT/US2007/004427 patent/WO2007100563A2/en active Application Filing
- 2007-02-20 CA CA2643145A patent/CA2643145C/en not_active Expired - Fee Related
- 2007-02-20 EP EP07751201A patent/EP1988925A2/en not_active Withdrawn
-
2008
- 2008-08-18 IL IL193518A patent/IL193518A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US8119103B2 (en) | 2012-02-21 |
IL193518A0 (en) | 2011-08-01 |
JP2009527559A (ja) | 2009-07-30 |
WO2007100563A2 (en) | 2007-09-07 |
US20090082324A1 (en) | 2009-03-26 |
EP1988925A2 (en) | 2008-11-12 |
WO2007100563A3 (en) | 2008-03-20 |
CA2643145A1 (en) | 2007-09-07 |
KR20080099279A (ko) | 2008-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090053137A1 (en) | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof | |
EP2341944B1 (en) | Conjugates of hexose and metal coordinating compounds for imaging purposes | |
CA2643145C (en) | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | |
TWI657827B (zh) | 用於正子斷層掃描之化合物 | |
US20100111858A1 (en) | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands | |
US20080279768A1 (en) | Bifunctional Metal Chelating Conjugates | |
WO2020065045A1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
US9061078B2 (en) | Tetraaza macrocyclic compound, preparation method thereof and use thereof | |
CN101316615A (zh) | 双官能金属螯合共轭物 | |
CN101389355A (zh) | 双功能间苯二酚、硫代间苯二酚和二硫代间苯二酚衍生物金属螯合共轭物 | |
CA3212963A1 (en) | Psma-targeting ligands with optimal properties for imaging and therapy | |
CN117642184A (zh) | 具有刷状缘膜酶可裂解接头的叶酸受体靶向缀合物以及在癌症成像和治疗中的使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170220 |
|
MKLA | Lapsed |
Effective date: 20170220 |